EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Assessment of Economic and Clinical Outcomes in Thai Patients With Respiratory Syncytial Virus Infection Across Age Groups: A Retrospective Cohort Analysis

Win Khaing, Chia Jie Tan iD, Chanthawat Patikorn iD, Chonnamet Techasaensiri, Oraluck Pattanaprateep, Teerapon Dhippayom, Jackrapong Bruminhent, Nathorn Chaiyakunapruk iD

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.70039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Win Khaing und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infections worldwide, including Thailand. This study aimed to assess clinical and economic burdens of RSV infections across different age groups in Thailand.

Method

A retrospective cohort study was conducted using data from a tertiary care hospital from 2014 to 2021. Patients who tested at least one positive RSV were included and stratified into five age groups (< 2, 2–5, 5–18, 18–65, and > 65 years). Healthcare resource utilization, direct medical costs, and clinical outcomes were analyzed with descriptive statistics. Generalized linear models with gamma distributions and log link were used to model cost outcomes. Costs were reported in 2021 US dollars (USD), with 1 USD = 31.98 Thai Baht.

Results

A total of 2122 RSV‐positive patients were identified, half of which (1097) were hospitalized. The median (interquartile range [IQR]) total hospitalization costs ranged from USD780 (IQR: USD488–USD1185) in those < 2 years to USD2231 (IQR: USD1250–USD4989) in those aged 65+ years. Case fatality rates among hospitalized patients also varied from 2.5% to 28.4% depending on age. Increased age, presence of comorbidities, and need for critical care were associated with higher hospitalization costs.

Conclusion

Among RSV‐positive patients, younger children experienced the greatest burden, but poorer outcomes were observed in older adults. Higher costs were associated with older age, comorbidities and critical care needs. Understanding RSV economic burdens is crucial for assessing the cost‐effectiveness and public health value of vaccination programs that prioritize at‐risk groups to mitigate the public health impact.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsHospitalizationHumansThailandRetrospective StudiesAdultChild, PreschoolFemaleAdolescentAgedMaleMiddle AgedChildYoung AdultInfantHealth Care CostsCost of IllnessRespiratory Syncytial Virus, HumanAge FactorsInfant, NewbornSoutheast Asian People

Stichwörter der Autor:innen

Thailandclinical outcomeseconomic outcomeshospitalizationreal‐world assessmentrespiratory syncytial virus

Autor:innen und Institutionen

  • Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA.
  • Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
  • Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • The Research Unit of Evidence Synthesis (TRUES), Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.
  • Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Chia Jie Tan, Chanthawat Patikorn, Nathorn Chaiyakunapruk

Förderung

  • NCATS NIH HHS

Zitieren

APA

Khaing, W., Tan, C. J., Patikorn, C., Techasaensiri, C., Pattanaprateep, O., Dhippayom, T., Bruminhent, J., & Chaiyakunapruk, N. (2024). Real‐World Assessment of Economic and Clinical Outcomes in Thai Patients With Respiratory Syncytial Virus Infection Across Age Groups: A Retrospective Cohort Analysis. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70039

Vancouver

Khaing W, Tan CJ, Patikorn C, Techasaensiri C, Pattanaprateep O, Dhippayom T, et al. Real‐World Assessment of Economic and Clinical Outcomes in Thai Patients With Respiratory Syncytial Virus Infection Across Age Groups: A Retrospective Cohort Analysis. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.70039

BibTeX
@article{Khaing2024,
  author = {Khaing, Win and Tan, Chia Jie and Patikorn, Chanthawat and Techasaensiri, Chonnamet and Pattanaprateep, Oraluck and Dhippayom, Teerapon and Bruminhent, Jackrapong and Chaiyakunapruk, Nathorn},
  title = {Real‐World Assessment of Economic and Clinical Outcomes in Thai Patients With Respiratory Syncytial Virus Infection Across Age Groups: A Retrospective Cohort Analysis},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.70039}
}
Kostenlos starten →